ZD-9379

Cat. No.:	HY-106968
CAS No.:	170142-20-8
Molecular Formula:	$C_{19}H_{14}ClN_3O_4$
Molecular Weight:	383.79
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect[1][2].
In Vivo	ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)[1]
Dosage:	5 mg/kg
Administration:	Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours.
Result:	Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.

REFERENCES

[1]. Tatlisumak T, et al. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke. 1998;29(1):190-195.

[2]. ZD 9379. Drugs R D. 1999;1(1):44-45.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA